Octagon Capital Advisors »

Black Diamond Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.6M 594k 4.35

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals (APLS)
Verona Pharma Sponsored Ads (VRNA)
Structure Therapeutics Sponsored Ads (GPCR)
Insmed Com Par $.01 Call Option (INSM)
Dianthus Therapeutics (DNTH)
Arrivent Biopharma (AVBP)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Nuvation Bio Com Cl A (NUVB)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Ocular Therapeutix (OCUL)
Miragen Therapeutics (VRDN)
Perspective Therapeutics Com New (CATX)
Mind Medicine Mindmed Com New (MNMD)
Cogent Biosciences (COGT)
Bridgebio Pharma (BBIO)

View all positions for Octagon Capital Advisors

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Bellevue Group
Vestal Point Capital
NEA Management Company
BlackRock
BlackRock
Vanguard Group
Ikarian Capital
Tang Capital Management
Siren
Geode Capital Management
ExodusPoint Capital Management
Citadel Advisors
Kennedy Capital Management
Point72 Asset Management

View all funds holding Black Diamond Therapeutics